Priming of human eosinophils by platelet-activating factor enhances the number of cells able to bind and respond to opsonized particles.
Addition of platelet-activating factor (PAF) to human eosinophils leads to the modulation of eosinophil responses. Earlier work from our laboratory has shown that the respiratory burst and homotypic aggregation response in these cells induced by opsonized particles (serum-treated zymosan, STZ), is strongly enhanced after pretreatment (priming) with PAF. In the present study we have investigated the effect of PAF on the binding of fluorescent STZ particles to human eosinophils. Addition of STZ to eosinophils isolated from the peripheral blood of normal donors results in an interaction of the STZ particles with only 30 to 40% of the cells. Treatment of the eosinophils with PAF (1 microM) for 2 min strongly enhanced the rate of particle binding and also doubled the percentage of eosinophils binding STZ. The effect of PAF priming is most likely mediated by a change in CR3, because it is reversed by mAb B2.12 blocking the iC3b binding site of CR3 and unaffected by mAb IV.3 blocking Fc gamma RII. This change is not an increase in cell surface expression of CR3, and it requires an active cellular metabolism to be maintained. The functional consequences of the effect of PAF on STZ binding were investigated in the nitro-blue tetrazolium dye slide test. PAF priming strongly enhanced the percentage of eosinophils producing oxygen radicals after STZ stimulation. Our findings indicate that the priming phenomenon observed in human eosinophils consists, at least in part, of a recruitment of cells able to interact with and to respond to opsonized particles.
Blom
M
M
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Tool
A T
AT
Roos
D
D
Verhoeven
A J
AJ
D000255:Adenosine Triphosphate / Q000378:metabolism; D003179:Complement C3b / Q000378:metabolism; D004734:Energy Metabolism; D004804:Eosinophils / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D010587:Phagocytosis; D010972:Platelet Activating Factor / Q000494:pharmacology*; D016897:Respiratory Burst; D013696:Temperature; D015054:Zymosan / Q000276:immunology
D010972:Platelet Activating Factor; D003179:Complement C3b; D000255:Adenosine Triphosphate; D015054:Zymosan